Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: HIV Prevention
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; Merck
Not yet recruiting - verified March 2010
Condition: Spinal Cord Injury
Interventions: Device: ReJoyce Workstation; Other: Standard Care
Sponsors: University of Melbourne; Victorian Neurotrauma Initiative; Life Time Care and Support Authority (NSW); University of Western Australia
Recruiting - verified March 2010
Conditions: Metabolic Syndrome; Hypercholesterolemia
Intervention: Drug: Metformin
Sponsor: Sydney West Area Health Service
Recruiting - verified February 2010
Condition: Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Intervention: Drug: intravitreal brimonidine tartrate implant using Posterior Segment Drug Delivery System (PS DDS®) Applicator
Sponsor: Allergan
Recruiting - verified February 2010
Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010
Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Not yet recruiting - verified March 2010
Condition: Cardiovascular Diseases
Interventions: Drug: polypill; Drug: Usual cardiovascular medications
Sponsors: Imperial College London; European Commission; Imperial College Healthcare NHS Trust; Royal College of Surgeons, Ireland; UMC Utrecht; The George Institute for International Health India; Public Health Foundation of India; The George Institute; Dr. Reddy's Laboratories Limited
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Gastric Cancer
Interventions: Drug: trastuzumab; Drug: fluorouracil; Drug: cisplatin; Drug: capecitabine
Sponsors: Hoffmann-La Roche; Chugai Pharmaceutical
Active, not recruiting - verified February 2010
Condition: Muscle Spasticity
Intervention:
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Treprostinil diethanolamine
Sponsor: United Therapeutics
Active, not recruiting - verified March 2010
Condition: Bronchiectasis
Intervention: Drug: mannitol
Sponsor: Pharmaxis
Completed - verified February 2010
Condition: Retinal Vein Occlusion
Interventions: Drug: VEGF Trap-Eye (BAY86-5321); Other: Sham treatment
Sponsors: Bayer; Regeneron Pharmaceuticals
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Sitagliptin
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Conditions: Duodenal Obstruction; Gastric Outlet Obstruction
Intervention: Device: EVOLUTION® Duodenal Stent
Sponsor: Cook
Recruiting - verified March 2010
Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: gemcitabine; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Bronchiectasis
Interventions: Drug: Cipro (Ciprofloxacin, BAYQ3939); Drug: Placebo
Sponsors: Bayer; Novartis
Recruiting - verified February 2010
Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hematologic Malignancies
Intervention: Drug: GSK21110183
Sponsor: Octagon Research Solutions, Inc.
Recruiting - verified February 2010
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY63-2521)
Sponsor: Bayer
Enrolling by invitation - verified February 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: RO5072759; Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone); Drug: FC(fludarabine,cyclophosphamide)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Oral Contraceptive; Headache; Pelvic Pain
Interventions: Drug: EV/DNG (Qlaira, BAY86-5027); Drug: Encapsulated Microgynon + Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Hypertension
Interventions: Drug: Aliskiren 150/Amlodipine 5 mg, 300/10 mg; Drug: Aliskiren 150/Hydrochlorothiazide 12.5 mg, 300/25 mg; Drug: Amlodipine 150/Hydrochlorothiazide 12.5 mg, 10/25 mg; Drug: Aliskiren 150/Amlodipine 5/Hydrochlorothiazide 12.5 mg, 300/10/25 mg
Sponsor: Novartis
Completed - verified March 2010
Condition: Alcoholism
Interventions: Drug: Org 25935; Drug: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Hepatitis B
Intervention: Other: Incentive condition
Sponsor: The National Centre in HIV Epidemiology and Clinical Research
Recruiting - verified February 2010
Condition: Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: Ixabepilone + Carboplatin; Drug: Paclitaxel + Carboplatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: Chronic Bronchitis
Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039); Drug: Amoxicillin clavulanic acid
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Macular Degeneration
Interventions: Drug: VEGF Trap-Eye (BAY86-5321); Drug: VEGF Trap-Eye (BAY86-5321); Drug: VEGF Trap-Eye (BAY86-5321); Drug: Ranibizumab
Sponsor: Bayer
Active, not recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Diseases Associated With Axonal Damage
Interventions: Drug: GSK249320; Drug: Placebo
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO4588161; Drug: RO4588161; Drug: RO4588161; Drug: Pegasys; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: rituximab [MabThera/Rituxan]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pelvic Organ Prolapse
Intervention: Procedure: Pelvic Floor Muscle Training
Sponsors: Glasgow Caledonian University; Chief Scientist Office of the Scottish Government; South Glasgow University Hospitals NHS Trust; University of Aberdeen; University of Otago
Active, not recruiting - verified February 2010
Condition: Duchenne Muscular Dystrophy
Intervention:
Sponsors: Cooperative International Neuromuscular Research Group; U.S. Department of Education; National Institutes of Health (NIH)
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Conditions: Venous Thrombosis; Deep Vein Thrombosis
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Conditions: Breast Neoplasms; Breast Tumors; Breast Cancer; Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 706 placebo; Drug: Bevacizumab; Drug: AMG 706
Sponsor: Amgen
Active, not recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Condition: Skin Cancer
Interventions: Drug: Carboplatin; Radiation: Radiotherapy
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Princess Alexandra Hospital, Brisbane, Australia; The Royal Australian and New Zealand College of Radiologists; The Princess Alexandra Hospital Cancer Collaborative Group
Recruiting - verified September 2009
Conditions: Transitional Cell Carcinoma; Bladder Neoplasms; Kidney Neoplasms; Ureter Neoplasms; Bladder Cancer; Neoplasm, Bladder
Intervention: Drug: vinflunine
Sponsors: Bristol-Myers Squibb; Pierre Fabre Medicament
Completed - verified August 2008
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
Sponsor: Biogen Idec
Completed - verified March 2010
Condition: HIV Infections
Interventions: Drug: Maraviroc (UK-427,857); Drug: optimized background therapy; Drug: Maraviroc (UK-427,857); Drug: optimized background therapy; Drug: optimized background therapy
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Condition: HIV-1
Interventions: Drug: Maraviroc + Zidovudine/Lamivudine; Drug: Efavirenz + Zidovudine/Lamivudine; Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Condition: Pulmonary Hypertension
Intervention: Drug: Ambrisentan
Sponsor: Gilead Sciences
Completed - verified March 2010
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Active, not recruiting - verified February 2010
Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
All Locations ... Australia » ... Sydney 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
